Notice Number: NOT-CA-20-051
Key Dates
Release Date: April 15, 2020
Issued by
National Cancer Institute (NCI)
Purpose
The purpose of this Notice is to revise the first receipt date for RFA-CA-20-004, and RFA-CA-20-005 Research Answers to National Cancer Institute's (NCI) Provocative Questions (R01/R21 Clinical Trial Optional)," for approximately one month.
In Part 1 of both RFAs, under Key Dates, the first receipt date now has a revised application due date of June 2, 2020.
I. Part 1 Key Dates in RFA-CA-20-004 and RFA-CA-20-005 Currently Reads:
Application Due Date(s):
April 30, 2020; November 17, 2020
No late applications will be accepted for this Funding Opportunity Announcement.
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Scientific Merit Review:
June/July 2020; February/March 2021
II. Part 1 Key Dates in RFA-CA-20-004 and RFA-CA-20-005 Modified (by this Notice) to Read (in italics):
Application Due Date(s):
June 2, 2020; November 17, 2020
No late applications will be accepted for this Funding Opportunity Announcement.
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Scientific Merit Review:
September/October 2020; February/March 2021
III. Part 1 Key Dates in RFA-CA-20-004 and RFA-CA-20-005 Remain Unmodified:
Advisory Council Review
January 2021; May 2021
Earliest Start Date
April 2021; July 2021 (R21)/September 2021 (R01)
Expiration Date
November 18, 2020
NOTE: All other aspects of these funding opportunity announcements (RFA-CA-20-004 and RFA-CA-20-005) remain unchanged.
Inquiries
Please direct all inquiries to:
Sean Hanlon, Ph.D.,
National Cancer Institute (NCI)
Telephone: 240-781-3310
Email: [email protected]
and Human Services (HHS)
